Health Care • Biotechnology: Pharmaceutical Preparations
$36.91 ▼ -0.61
(-1.63%)
MKT CAP: $27.10B • VOL: 4.57M
52W L $19 52W H $43
ROIV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $8.3M | $29.1M | $32.7M |
| YoY Revenue Growth % | -71.6% | -11.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$515.1M | -$1.00B | $4.50B |
| Operating Margin % | -6235.7% | -3453.3% | 13746.9% |
| Net Income (GAAP) | -$299.8M | -$172.0M | $4.35B |
| EBITDA (Normalized) | -$508.5M | -$999.6M | $4.50B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$750.3M | -$839.5M | -$765.3M |
| Capital Expenditures (CapEx) | $8.2M | $4.6M | $1.5M |
| Free Cash Flow (FCF) | -$758.6M | -$844.0M | -$766.7M |
| FCF Margin % | -9183.5% | -2905.2% | -2343.8% |
| Return on Invested Capital (ROIC %) | -14.0% | -23.9% | 39.5% |
| Cash & Short-Term Equivalents | $1.48B | $1.99B | — |
| Total Debt (Short + Long Term) | $113.0M | $115.4M | $3.49B |
| Total Stockholders' Equity | $4.27B | $5.19B | $7.15B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ROIV.